Johnson & Johnson Stock - Analyst views and operations in focus
Published on 06/17/2026 at 21:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 21:26 CET. Details in the imprint.
Johnson & Johnson (US4781601046) remains one of the largest global healthcare companies by market value. With no fresh earnings or regulatory headlines on Wednesday, the focus turns to how analysts view the stock and how the diversified operations underpin its long-term profile.
All news and data on Johnson & Johnson stock
Key figures, regulatory filings and background on Johnson & Johnson give additional context for how the healthcare group’s stock trades in global markets.
Analyst consensus on the stock
Analyst coverage of Johnson & Johnson remains broad, with most major houses rating the stock around neutral to moderately positive based on its diversified earnings base and strong balance sheet. Aggregate data show a mix of Buy, Hold and a few Sell recommendations.
Consensus expectations point to modest single-digit revenue growth over the next few years, driven mainly by pharmaceuticals and medtech while consumer health is now separated into Kenvue. The dividend track record continues to be a core argument for many long-term holders.
Operations and strategy on Wednesday’s radar
Operationally, Johnson & Johnson is structured around two main segments after the Kenvue spin-off: Innovative Medicine and MedTech. The Innovative Medicine unit focuses on areas such as oncology, immunology, neuroscience and cardiovascular disease.
The MedTech segment supplies devices and solutions for surgery, orthopedics, interventional procedures and vision care. Management highlights a strategy centered on high-margin, high-barrier therapies and devices, supported by continued research and development spending.
The product behind the stock
Behind the stock, Johnson & Johnson generates most of its revenue from prescription medicines for oncology and immunology as well as medical devices for surgery and orthopedics. Well-known consumer brands like Tylenol and Johnson’s baby products remain associated with the name but are now largely within Kenvue.
Where the stock trades today
Johnson & Johnson shares (US4781601046) trade on the New York Stock Exchange at around $140.00 as of 06/17/2026, 21:20 CET, reflecting the latest available composite quote in US dollars.
Key facts on Johnson & Johnson stock
- Company: Johnson & Johnson Inc.
- ISIN: US4781601046
- WKN: 853260
- Ticker: JNJ
- Venue: New York Stock Exchange
- Price (as of 06/17/2026, 21:20 CET): 140.00 USD
- Market cap: 340,000,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Medical Devices
- Index membership: Dow Jones Industrial Average, S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
